[go: up one dir, main page]

AR066995A1 - Composicion farmeceutica sobre la base de inhibidor de transcriptasa inversa y meldonio - Google Patents

Composicion farmeceutica sobre la base de inhibidor de transcriptasa inversa y meldonio

Info

Publication number
AR066995A1
AR066995A1 ARP060103527A ARP060103527A AR066995A1 AR 066995 A1 AR066995 A1 AR 066995A1 AR P060103527 A ARP060103527 A AR P060103527A AR P060103527 A ARP060103527 A AR P060103527A AR 066995 A1 AR066995 A1 AR 066995A1
Authority
AR
Argentina
Prior art keywords
meldonium
pharmeceutic
inverse
composition
base
Prior art date
Application number
ARP060103527A
Other languages
English (en)
Inventor
Vija Klusa
Sergejs Isajevs
Ivars Kalvins
Valentina Gordjusina
Immanuels Taivans
Original Assignee
Grindeks Jsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066995(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grindeks Jsc filed Critical Grindeks Jsc
Publication of AR066995A1 publication Critical patent/AR066995A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se han descripto novedosas composiciones farmacéuticas para tratar infecciones retrovirales por medio de su utilizacion enteral y parenteraI, que contienen uno de los inhibidores de la transcriptasa inversa, a saber zidovudina (AZT), lamivudina, o stavudina en cantidad clínicamente eficaz y meldonio así como también excipientes farmacéuticos aplicables. Se ha comprobado que la inclusion de meldonio en estas composiciones farmacéuticas disminuye esencialmente la cardio y neuro-toxicidad del inhibidor de la transcriptasa inversa sin reduccion de su eficacia antiviral.
ARP060103527A 2005-08-15 2006-08-11 Composicion farmeceutica sobre la base de inhibidor de transcriptasa inversa y meldonio AR066995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium

Publications (1)

Publication Number Publication Date
AR066995A1 true AR066995A1 (es) 2009-09-30

Family

ID=37442067

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103527A AR066995A1 (es) 2005-08-15 2006-08-11 Composicion farmeceutica sobre la base de inhibidor de transcriptasa inversa y meldonio

Country Status (17)

Country Link
US (1) US7700576B2 (es)
EP (1) EP1933823B1 (es)
JP (1) JP5027809B2 (es)
CN (1) CN101252925B (es)
AR (1) AR066995A1 (es)
AT (1) ATE493123T1 (es)
DE (1) DE602006019293D1 (es)
EE (1) EE05529B1 (es)
ES (1) ES2361185T3 (es)
HN (1) HN2006029085A (es)
LT (1) LT5524B (es)
LV (1) LV13544B (es)
PE (1) PE20070233A1 (es)
SV (1) SV2007002655A (es)
UA (1) UA90162C2 (es)
UY (1) UY29751A1 (es)
WO (1) WO2007021164A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766048A1 (en) 2009-06-25 2010-12-29 Tetra, Sia Novel acetylsalicylic acid salts
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompoz&imacr;cija trimetilam&imacr;na-N-oks&imacr;da l&imacr;me&ncedil;a pazemin&amacr;&scaron;anai

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU997646A1 (ru) 1978-11-27 1983-02-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Кормова добавка
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IT1255039B (it) 1992-03-11 1995-10-13 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento di pazienti hiv-sieropositivi presentanti deficit di carnitina.

Also Published As

Publication number Publication date
UA90162C2 (ru) 2010-04-12
EP1933823A1 (en) 2008-06-25
ATE493123T1 (de) 2011-01-15
EE05529B1 (et) 2012-04-16
WO2007021164A1 (en) 2007-02-22
LT5524B (lt) 2008-10-27
UY29751A1 (es) 2007-03-30
JP5027809B2 (ja) 2012-09-19
LT2008003A (en) 2008-07-25
US7700576B2 (en) 2010-04-20
LV13544B (en) 2007-05-20
ES2361185T3 (es) 2011-06-14
US20090137522A1 (en) 2009-05-28
PE20070233A1 (es) 2007-06-08
CN101252925A (zh) 2008-08-27
DE602006019293D1 (de) 2011-02-10
JP2009504731A (ja) 2009-02-05
SV2007002655A (es) 2007-04-12
EE200800014A (et) 2008-06-16
EP1933823B1 (en) 2010-12-29
CN101252925B (zh) 2012-04-25
HN2006029085A (es) 2007-11-16

Similar Documents

Publication Publication Date Title
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
CL2023000555A1 (es) Compuestos y métodos para el tratamiento de infecciones virales
CL2008001631A1 (es) Compuestos derivados de heterociclos sustituidos, con la presencia de un grupo fenoxi, inhibidores de transcriptasa inversa; composicion farmaceutica; y uso en el tratamiento de infecciones virales por vih.
CR20240363A (es) Compuestos y métodos para el tratamiento de infecciones virales.
ECSP099373A (es) Inhibidores de transcriptasa inversa no nucleosídicos
ECSP10010210A (es) Compuestos nucleósidos antivirales
CR11316A (es) Derivado de uracilo o timina para el tratamiiento de la hepatitis c.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008001756A1 (es) Agente de arn de interferencia (iarn); composicion farmaceutica que lo comprende; y su uso para tratar procesos patologicos mediados al menos en parte por la expresion del canal de sodio epitelial alfa (alfa-enac)
GT200600341A (es) Inhibidores macrociclicos del virus de la hepatitis c
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
UY29266A1 (es) Compuestos de piridazinona
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
ES2380951T3 (es) Diaril-purinas, -azapurinasy - desazapurinas como inhibidores no nucleósidos de la transcriptasa inversa para el tratamiento del VIH
ECSP088635A (es) Formulaciones orales que comprenden tigeciclina
CY1109440T1 (el) Φωσφοϊνδολες ως αναστολεις hiv
DOP2024000172A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
AR066995A1 (es) Composicion farmeceutica sobre la base de inhibidor de transcriptasa inversa y meldonio
PA8590801A1 (es) Derivados de nucleosido antivirales
DK2099461T3 (da) LNA Nukleoside Phosphoramidates
CL2024002624A1 (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
EP4194466A4 (en) Antiviral composition against coronavirus
MX2020002008A (es) Tratamientos antivirales intravenosos.
DOP2006000189A (es) Composición farmacéutica basal del inhibidor de transcriptasa reversa y meldonio

Legal Events

Date Code Title Description
FB Suspension of granting procedure